| Literature DB >> 35022460 |
Lu Zhao1, Shuang Cao1, Lulu Pei1, Hui Fang1, Hao Liu2, Jun Wu1, Shilei Sun1, Yuan Gao1, Bo Song3, Yuming Xu4.
Abstract
It is essential to identify high risk transient ischemic attack (TIA) patients. The previous study reported that the CSR (comprehensive stroke recurrence) model, a neuroimaging model, had a high predictive ability of recurrent stroke. The aims of this study were to validate the predictive value of CSR model in TIA patients and compare the predictive ability with ABCD3-I score. Data were analyzed from the prospective hospital-based database of patients with TIA which defined by the World Health Organization time-based criteria. The predictive outcome was stroke occurrence at 90 days. The receiver-operating characteristic (ROC) curves were plotted and the C statistics were calculated as a measure of predictive ability. Among 1186 eligible patients, the mean age was 57.28 ± 12.17 years, and 474 (40.0%) patients had positive diffusion-weighted imaging (DWI). There were 118 (9.9%) patients who had stroke within 90 days. In 1186 TIA patients, The C statistic of CSR model (0.754; 95% confidence interval [CI] 0.729-0.778) was similar with that of ABCD3-I score (0.717; 95% CI 0.691-0.743; Z = 1.400; P = 0.1616). In 474 TIA patients with positive DWI, C statistic of CSR model (0.725; 95% CI 0.683-0.765) was statistically higher than that of ABCD3-I score (0.626; 95% CI 0.581-0.670; Z = 2.294; P = 0.0245). The CSR model had good predictive value for assessing stroke risk after TIA, and it had a higher predictive value than ABCD3-I score for assessing stroke risk for TIA patients with positive DWI.Entities:
Mesh:
Year: 2022 PMID: 35022460 PMCID: PMC8755815 DOI: 10.1038/s41598-021-04405-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Comprehensive stroke recurrence (CSR) model.
| CSR model | |
|---|---|
| Multiple stage lesion | 3 |
| Isolated cortical lesion | 1 |
| Severe white matter hyperintensity | 1 |
| 0 | 0 |
| 1–2 | 1 |
| > 2 | 2 |
| Relevant arterial stenosis | 1 |
Baseline characteristics of enrolled TIA participants.
| All TIA patients (n = 1186) | TIA patients with negative DWI (n = 712) | TIA patients with positive DWI (n = 474) | ||
|---|---|---|---|---|
| Age ≥ 60 | 531 (44.8%) | 312 (43.8%) | 219 (46.2%) | 0.419 |
| Male | 719 (60.6%) | 409 (57.4%) | 310 (65.4%) | 0.006 |
| Current smoking | 335 (28.3%) | 170 (23.9%) | 165 (35.0%) | < 0.001 |
| DWI in 3 days | 953 (80.4%) | 562 (78.9%) | 391 (82.5%) | 0.131 |
| Hypertension | 650 (54.8%) | 370 (52.0%) | 280 (59.1%) | 0.016 |
| Diabetes | 207 (17.5%) | 113 (15.9%) | 94 (19.8%) | 0.078 |
| Dyslipidemia | 227 (19.1%) | 129 (18.1%) | 98 (20.7%) | 0.273 |
| Coronary heart disease | 154 (13.0%) | 95 (13.3%) | 59 (12.4%) | 0.653 |
| Atrial fibrillation | 26 (2.2%) | 11 (1.5%) | 15 (3.2%) | 0.062 |
| History of stroke | 248 (20.9%) | 136 (19.1%) | 112 (23.6%) | 0.060 |
| ABCD3-I score (median, IQR) | 5 (4–7) | 5 (4–7) | 7 (6–9) | < 0.001 |
| CSR score (median, IQR) | 1 (0–2) | 1 (0–2) | 4 (1–6) | < 0.001 |
| Antiplatelet agents | 1116 (94.1%) | 664 (93.3%) | 452 (95.4%) | 0.133 |
| Anticoagulant | 38 (3.2%) | 13 (1.8%) | 25 (5.3%) | 0.001 |
| Lipid-lowering agents | 1108 (93.4%) | 660 (92.7%) | 448 (94.5%) | 0.216 |
| Antihypertension agents | 398 (33.6%) | 239 (33.6%) | 159 (33.5%) | 0.993 |
| Hypoglycemic agents | 230 (19.4%) | 126 (17.7%) | 104 (21.9%) | 0.070 |
TIA transient ischemic attack, DWI diffusion-weighted imaging, CSR comprehensive stroke recurrence.
Figure 1Stroke risk at 90 days according to CSR score.
Figure 2(A) Kaplan–Meier curves of TIA patients stratified according to the CSR model at 90 days (log-rank test = 121.70, P < 0.001); (B) Kaplan–Meier curves of DWI-positive subjects stratified according to the CSR model at 90 days (log-rank test = 33.75, P < 0.001); (C) Kaplan–Meier curves of DWI-negative subjects stratified according to the CSR model at 90 days (log-rank test = 6.89, P = 0.142).
Baseline characteristics and risk factors of patients with and without recurrence at 90 days.
| Stroke occurrence at 90 days | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIA patients (n = 1186) | TIA patients with positive DWI (n = 474) | TIA patients with negative DWI (n = 712) | |||||||
| No (n = 1068) | Yes (n = 118) | No (n = 387) | Yes (n = 87) | No (n = 681) | Yes (n = 31) | ||||
| Age ≥ 60 years | 469 (43.9%) | 62 (52.5%) | 0.074 | 172 (44.4%) | 47 (54.0%) | 0.105 | 297 (43.6%) | 15 (48.4%) | 0.600 |
| Male | 646 (60.5%) | 73 (61.9%) | 0.771 | 260 (67.2%) | 50 (57.5%) | 0.085 | 386 (56.7%) | 23 (74.2%) | 0.054 |
| Current smoking | 295 (27.7%) | 40 (33.9%) | 0.158 | 137 (35.7%) | 28 (32.2%) | 0.537 | 158 (23.2%) | 12 (38.7%) | 0.078 |
| DWI in 3 days | 857 (80.2%) | 96 (81.4%) | 0.773 | 319 (82.4%) | 72 (82.8%) | 0.942 | 538 (79%) | 24 (77.4%) | 0.833 |
| Hypertension | 566 (53.0%) | 84 (71.2%) | < 0.001 | 215 (55.6%) | 65 (74.7%) | 0.001 | 351 (51.5%) | 19 (61.3%) | 0.288 |
| Diabetes | 186 (17.4%) | 21 (17.8%) | 0.918 | 77 (19.9%) | 17 (19.5%) | 0.940 | 109 (16.0%) | 4 (12.9%) | 0.833 |
| Dyslipidemia | 203 (19.0%) | 24 (20.3%) | 0.727 | 83 (21.4%) | 15 (17.2%) | 0.381 | 120 (17.6%) | 9 (29.0%) | 0.107 |
| Coronary heart disease | 138 (12.9%) | 16 (13.6%) | 0.845 | 48 (12.4%) | 11 (12.6%) | 0.951 | 90 (13.2%) | 5 (16.1%) | 0.641 |
| Atrial fibrillation | 25 (2.3%) | 1 (0.8%) | 0.472 | 14 (3.6%) | 1 (1.1%) | 0.396 | 11 (1.6%) | 0 (0%) | – |
| History of stroke | 217 (20.3%) | 31 (26.3%) | 0.131 | 85 (22.0%) | 27 (31.0%) | 0.072 | 132 (19.4%) | 4 (12.9%) | 0.507 |
| Unilateral weakness | 122 (11.4%) | 16 (13.6%) | < 0.001 | 50 (12.9%) | 11 (12.6%) | 0.067 | 72 (10.6%) | 5 (16.1%) | 0.208 |
| Speech disturbance without weakness | 569 (53.3%) | 82 (69.5%) | 240 (62.0%) | 64 (73.6%) | 329 (48.3%) | 18 (58.1%) | |||
| < 10 min | 441 (41.3%) | 32 (27.1%) | 0.004 | 144 (37.2%) | 24 (27.6%) | 0.125 | 297 (43.6%) | 8 (25.8%) | 0.124 |
| 10–59 min | 411 (38.5%) | 63 (53.4%) | 164 (42.4%) | 47 (54.0%) | 247 (36.3%) | 16 (51.6%) | |||
| ≥ 60 min | 216 (20.2%) | 23 (19.5%) | 79 (20.4%) | 16 (18.4%) | 137 (20.1%) | 7 (22.6%) | |||
| ABCD3-I score (median, IQR) | 5 (4–7) | 7 (6–9) | < 0.001 | 7 (6–9) | 8 (7–10) | < 0.001 | 4 (3–6) | 5 (4–6) | 0.092 |
| Multiple stage lesion | 119 (11.1%) | 56 (47.5%) | < 0.001 | 119 (30.7%) | 56 (64.4%) | < 0.001 | … | … | – |
| Isolated cortical lesion | 161 (15.1%) | 46 (39.0%) | < 0.001 | 161 (41.6%) | 46 (52.9%) | 0.055 | … | … | – |
| Severe WMH | 193 (18.1%) | 41 (34.7%) | < 0.001 | 104 (26.9%) | 37 (42.5%) | 0.004 | 89 (13.1%) | 4 (12.9%) | 0.979 |
| 0 | 555 (52.0%) | 32 (27.1%) | < 0.001 | 177 (45.7%) | 19 (21.8%) | < 0.001 | 378 (55.5%) | 13 (41.9%) | 0.066 |
| 1–2 | 369 (34.6%) | 54 (45.8%) | 148 (38.2%) | 44 (50.6%) | 221 (32.5%) | 10 (32.3%) | |||
| > 2 | 144 (13.5%) | 32 (27.1%) | 62 (16.0%) | 24 (27.6%) | 82 (12.0%) | 8 (25.8%) | |||
| Relevant arterial stenosis | 185 (17.3%) | 57 (48.3%) | < 0.001 | 184 (47.5%) | 57 (65.5%) | 0.002 | 1 (0.1%) | 0 (0%) | – |
| CSR score (median, IQR) | 1 (0–2) | 4 (1–6) | < 0.001 | 2 (1–4) | 5 (3–6) | < 0.001 | 0 (0–1) | 1 (1–2) | 0.078 |
| Antiplatelet agents | 1006 (96.3%) | 110 (95.7%) | 0.743 | 371 (95.9%) | 81 (93.1%) | 0.268 | 635 (93.2%) | 29 (93.5%) | 0.948 |
| Anticoagulant | 35 (3.3%) | 3 (2.5%) | 0.877 | 22 (5.7%) | 3 (3.4%) | 0.563 | 13 (1.9%) | 0 (0%) | – |
| Lipid-lowering agents | 996 (93.3%) | 112 (94.9%) | 0.491 | 364 (94.1%) | 84 (96.6%) | 0.507 | 632 (92.8%) | 28 (90.3%) | 0.868 |
| Antihypertension agents | 356 (33.3%) | 42 (35.6%) | 0.622 | 127 (32.8%) | 32 (36.8%) | 0.479 | 229 (33.6%) | 10 (32.3%) | 0.875 |
| Hypoglycemic agents | 206 (19.3%) | 24 (20.3%) | 0.784 | 85 (22.0%) | 19 (21.8%) | 0.980 | 121 (17.8%) | 5 (16.1%) | 0.815 |
Statistical analysis not possible owing to absence of events in the group of TIA patients with negative DWI.
TIA transient ischemic attack, DWI diffusion-weighted imaging, CSR comprehensive stroke recurrence, OLI old lacunar infarction.
Figure 3Ninety-day receiver-operating characteristic curves as a predictive value of the CSR score and ABCD3-I score. (A) The C statistic of CSR model (0.754; 95% CI 0.729–0.778) was similar with that of ABCD3-I score (0.717; 95% CI 0.691–0.743, Z = 1.400; P = 0.1616) in TIA patients; (B) CSR score showed better discrimination (Z = 2.294, P = 0.0245) with the C statistic of 0.725 (95% CI 0.683–0.765) than ABCD3-I score (0.626; 95% CI 0.581–0.670) in DWI-positive subjects. (C) The C statistic of CSR model (0.585; 0.548–0.622) was similar with that of ABCD3-I score (0.588; 0.551–0.624, Z = 0.0362; P = 0.9711) in TIA patients with negative DWI.